News &amp; Updates

New drug applications approved by US FDA as of 16-28 February 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 28 February 2022)

Add-on electrostimulation of no benefit to paediatric cystic fibrosis patients

A resistance exercise-training program is enough to yield gains in muscle strength and functional capacity in paediatric cystic fibrosis (CF) patients with mild-to-moderate pulmonary impairment, a study has found. Meanwhile, the addition of neuromuscular electrical stimulation (NMES) does not appear to provide extra benefit.

Add-on electrostimulation of no benefit to paediatric cystic fibrosis patients

Wearable defibrillator helps avoid sudden cardiac death after surgery

02 Mar 2022 by

Wearable cardioverter defibrillators (WCD) can effectively protect cardiac surgery patients from sudden cardiac death (SCD), according to a recent study, noting that SCD risk was substantial within the first 3 months after the procedure.

Wearable defibrillator helps avoid sudden cardiac death after surgery

Continuity of care cuts ASCVD risk in newly diagnosed dyslipidaemic patients

Good continuity of care (COC) helps prevent atherosclerotic cardiovascular disease (ASCVD) in patients with newly diagnosed dyslipidaemia, a recent Korea study has found.

Continuity of care cuts ASCVD risk in newly diagnosed dyslipidaemic patients

Mucolytics, ICS/LABA combinations cut stroke risk among COPD patients with allied conditions

Patients with chronic obstructive pulmonary disease (COPD) and allied conditions are at heightened risk of stroke, but treatment with mucolytic agents and the combination of inhaled corticosteroids (ICS) plus long-acting β2-agonists (LABA) may protect against the risk, as shown in a study.

Mucolytics, ICS/LABA combinations cut stroke risk among COPD patients with allied conditions

Dihydropyridine CCB lowers visit-to-visit BP variability

Regular use of a dihydropyridine calcium channel blocker (CCB) results in a 2-mm Hg decrease in visit-to-visit blood pressure variability (vvBPV), according to the results of a post hoc analysis of the SPRINT trial.

Dihydropyridine CCB lowers visit-to-visit BP variability

Working longer hours contributes to hypertension risk

Men and women who work long hours have higher blood pressure levels compared with their counterparts who work 35–40 hours per week, a study reports.

Working longer hours contributes to hypertension risk